Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chronic Lymphocytic Leukemia
100%
Overall Survival
19%
Confidence Interval
15%
Richter Transformation
12%
Ibrutinib
11%
Infection Risk
11%
Time-to-treatment
11%
Chemotherapy
10%
Bloodstream Infection
10%
Tumor Protein p53 (TP53)
10%
Epidemiology
10%
Real-world Outcomes
10%
Malignancy
10%
Hospitalization
10%
Pre-diagnostic
10%
Newly Diagnosed Patients
9%
COVID-19
9%
Antimicrobial Use
9%
Comorbidity
8%
Multiple Myeloma
8%
High Risk
8%
Clinical Impact
7%
Leukemia Patients
7%
Danish Population
6%
Prognostic Significance
6%
Risk Factors
6%
TP53 mutation
6%
Clinical Outcomes
6%
Statins
6%
Cardiovascular Disease
6%
Retrospective Cohort Study
6%
Cause of Death
6%
Treatment-free Survival
6%
Newly Diagnosed
6%
Incidence Rate
5%
Hematological Malignancies
5%
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
5%
Register Study
5%
Low-density Lipoprotein Cholesterol Level
5%
Case-time-control
5%
Neurological Events
5%
Radiotherapy
5%
Cytopenia
5%
Deep Targeted Sequencing
5%
Increased Incidence
5%
Long-term Clinical Outcome
5%
Multi-hit
5%
Metronidazole
5%
Early Death
5%
Vaccine Effectiveness
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
61%
Infection
30%
Cohort Study
22%
Malignant Neoplasm
14%
Ibrutinib
12%
Overall Survival
12%
Chemotherapy
10%
Pharmacogenetics
10%
Adverse Event
9%
Antiinfective Agent
8%
Multiple Myeloma
8%
Cardiovascular Disease
7%
Comorbidity
7%
Hematologic Malignancy
7%
Progression Free Survival
6%
Adverse Drug Reaction
6%
Vaccination Policy
6%
Proprotein Convertase 9
5%
Hyperlipidemia
5%
Low Density Lipoprotein Cholesterol
5%
Cause of Death
5%
Solid Malignant Neoplasm
5%
Metronidazole
5%
Non Insulin Dependent Diabetes Mellitus
5%
Cytopenia
5%
Pneumococcal Infection
5%
Bloodstream Infection
5%
Reinfection
5%
SARS Coronavirus
5%
Nonhodgkin Lymphoma
5%
Minimal Residual Disease
5%
Paracetamol
5%
Acetylcysteine
5%
Toxic Injury
5%
Androgen
5%
Polypharmacy
5%
Statin (Protein)
5%
Hydralazine
5%
Acyltransferase
5%
Rituximab
5%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
71%
Infection
19%
Cohort Analysis
16%
Richter's Transformation
12%
Systematic Review
10%
Overall Survival
10%
Adverse Event
9%
Antiinfective Agent
8%
Hematologic Malignancy
7%
Retrospective Cohort Study
6%
Ibrutinib
6%
Adverse Drug Reaction
6%
Multiple Myeloma
5%
Bloodstream Infection
5%
Cytopenia
5%
Metronidazole
5%
Diagnosis
5%
Time to Treatment
5%
Maturity Onset Diabetes of the Young
5%
Lymphocytosis
5%
Pneumococcal Infection
5%
Cohort Effect
5%
Cause of Death
5%
Blood Culture
5%
Hypogammaglobulinemia
5%
Solid Malignant Neoplasm
5%
Radiation Therapy
5%
Opiate
5%
Analgesia
5%
Non-Hodgkin Lymphoma
5%
Androgen
5%
Cardiovascular Disease
5%
Pharmacogenetics
5%
Hospital Medicine
5%
